The Cost of Antivenom: A Cost Minimization Study using the North American Snakebite Registry
Antivenom is the primary cost driver in snakebite treatment in North America. Treatment with F(ab')<sub>2</sub> resulted in lower overall costs, driven by lower cost of antivenom. F(ab')<sub>2</sub> did not significantly lower overall resource use except for blood product administration.
Authors
- Paul Gavaza (ORCID: https://orcid.org/0000-0002-4538-8622)
- Brian Wolk
- Christopher Hoyte (ORCID: https://orcid.org/0000-0003-4301-3795)
- Benjamin Herzel (ORCID: https://orcid.org/0000-0003-3792-1850)
- Jakub Furmaga
- Tammy Phan
- Anne-Michelle Ruha
- Neev Batavia
- Emmelyn Samones
Institutions
- Loma Linda University (US)
- The Medical Center of Aurora (US)
- Southwestern Medical Center (US)
- Banner - University Medical Center Phoenix (US)
- Washington Poison Center (US)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Journal of Medical Toxicology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1007/s13181-025-01072-x
- Citations
- 3
- Primary Topic
- Venomous Animal Envenomation and Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.45
Funders
- Loma Linda University